https://www.pdsbiotech.com/index.php/investors/news-center/press-releases/press-releases1/134-2026-news/1035-pds-biotech-announces-publication-of-positive-pds01adc-inter2026-04-15-055033
PDS Biotech - PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial...
pds biotech announcespublicationpositiveinterimphase
https://www.pdsbiotech.com/index.php/investors/news-center/press-releases/press-releases1/131-2024-news/945-iotechnnouncespdatedesultsfrom002h20240916
PDS Biotech - PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial...
PDS Biotech is committed to developing novel and effective therapies based on the Versamune® platform to save and improve the lives of cancer patients...
pds biotech announcesupdatedresultsversatilephase
https://www.pdsbiotech.com/index.php/investors/news-center/press-releases/press-releases1/131-2024-news/952-iotechnnounces36onthverallurvivalateof8420241002
PDS Biotech - PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced...
PDS Biotech is committed to developing novel and effective therapies based on the Versamune® platform to save and improve the lives of cancer patients...
pds biotech announcesmonthoverallsurvivalrate
https://www.pdsbiotech.com/index.php/investors/news-center/press-releases/press-releases1/125-2023-news/885-iotechnnouncespdatedurvivalatafromedh20231109
PDS Biotech - PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of...
PDS Biotech is committed to developing novel and effective therapies based on the Versamune® platform to save and improve the lives of cancer patients...
pds biotech announcesclinical trialupdatedsurvivaldata